Sinapic Acid Ameliorates Doxorubicin-Induced Cardiotoxicity in H9c2 Cardiomyoblasts by Inhibiting Oxidative Stress Through Activation of the Nrf2 Signaling Pathway DOI Creative Commons

Tsendsuren Tungalag,

Hyung‐Sub Kang,

Dong Kwon Yang

и другие.

Antioxidants, Год журнала: 2025, Номер 14(3), С. 337 - 337

Опубликована: Март 13, 2025

The use of doxorubicin (Dox) is restricted because its cardiotoxicity, which poses a significant mortality risk for cancer patients, despite being highly effective antibiotic treating various types cancer. Therefore, identifying substances or developing preventive strategies against Dox-induced cardiotoxicity crucial. This study was conducted to determine whether sinapic acid (SA), phenolic compound with range pharmacological effects, could protect in H9c2 cardiomyoblasts. To investigate the effect SA, cardiomyoblasts treated Dox were pretreated SA at concentrations. effectively rescued cells from cardiotoxicity. Additionally, significantly reduced oxidative stress by inhibiting mitochondrial dysfunction and endoplasmic reticulum stress. also suppressed expression MAPK proteins. As underlying mechanism SA's protective activated nuclear factor erythroid-2-related (Nrf2) facilitating movement cytosol nucleus increasing target antioxidative genes. In summary, this demonstrated that protects activation Nrf2-related signaling pathway. Our findings enhance development therapeutic mitigate cardiac toxicity caused Dox, highlighting potential antioxidant Dox-treated

Язык: Английский

Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects DOI Creative Commons

Qin Ru,

Yusheng Li,

Lin Chen

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Окт. 14, 2024

Iron, an essential mineral in the body, is involved numerous physiological processes, making maintenance of iron homeostasis crucial for overall health. Both overload and deficiency can cause various disorders human diseases. Ferroptosis, a form cell death dependent on iron, characterized by extensive peroxidation lipids. Unlike other kinds classical unprogrammed death, ferroptosis primarily linked to disruptions metabolism, lipid peroxidation, antioxidant system imbalance. Ferroptosis regulated through transcription, translation, post-translational modifications, which affect cellular sensitivity ferroptosis. Over past decade or so, diseases have been as part their etiology, including cancers, metabolic disorders, autoimmune diseases, central nervous cardiovascular musculoskeletal Ferroptosis-related proteins become attractive targets many major that are currently incurable, some regulators shown therapeutic effects clinical trials although further validation potential needed. Therefore, in-depth analysis its molecular mechanisms may offer additional strategies prevention treatment. In this review, we discuss significance contribution etiology development along with evidence supporting targeting approach. Importantly, evaluate recent promising interventions, providing guidance future targeted treatment therapies against

Язык: Английский

Процитировано

75

The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors DOI Creative Commons
Mohamed S. Dabour,

Mina Y. George,

Mary R. Daniel

и другие.

JACC CardioOncology, Год журнала: 2024, Номер 6(2), С. 159 - 182

Опубликована: Март 12, 2024

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2 diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly heart failure, patients with and without diabetes. An intriguing research area involves exploring the potential application of SGLT2 inhibitors cardio-oncology, aiming to mitigate adverse events associated anticancer treatments. These present a unique dual nature, offering both cardioprotective effects properties, conferring double benefit cardio-oncology patients. In this review, authors first examine established failure subsequently explore existing body evidence, including preclinical clinical studies, that supports use context cardio-oncology. The further discuss mechanisms through which protect against toxicity secondary cancer treatment. Finally, they along their proposed mechanisms.

Язык: Английский

Процитировано

23

DOXORUBICIN-RELATED CARDIOTOXICITY: REVIEW OF FUNDAMENTAL PATHWAYS OF CARDIOVASCULAR SYSTEM INJURY DOI
Ashot Avagimyan, Nana Pogosova, L. V. Kakturskiy

и другие.

Cardiovascular Pathology, Год журнала: 2024, Номер 73, С. 107683 - 107683

Опубликована: Авг. 6, 2024

Язык: Английский

Процитировано

19

Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure DOI Creative Commons
Matteo Armillotta,

Francesco Angeli,

Pasquale Paolisso

и другие.

Pharmacology & Therapeutics, Год журнала: 2025, Номер 270, С. 108861 - 108861

Опубликована: Апрель 15, 2025

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are oral antidiabetic agents that have shown significant improvements in cardiovascular and renal outcomes among patients with heart failure (HF), regardless of diabetic status, establishing them as a cornerstone therapy. In addition to glycemic control the osmotic diuretic effect, inhibition SGLT2 improves endothelial function vasodilation, optimizing myocardial energy metabolism preserving cardiac contractility. Moreover, may exhibit anti-inflammatory properties attenuate acute ischemia/reperfusion injury, thereby reducing infarct size, enhancing left ventricular function, mitigating arrhythmias. These pleiotropic effects demonstrated efficacy across various conditions, ranging from chronic coronary syndromes extending arrhythmias, valvular disease, cardiomyopathies, cardio-oncology, cerebrovascular disease. This review provides an overview current literature on potential mechanisms underlying effectiveness wide range diseases beyond HF.

Язык: Английский

Процитировано

3

Inflammation, oxidative stress and mitochondrial dysfunction in the progression of type II diabetes mellitus with coexisting hypertension DOI Creative Commons

Hibba Yousef,

Ahsan H. Khandoker, Samuel F. Feng

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Июнь 13, 2023

Type II diabetes mellitus (T2DM) is a metabolic disorder that poses serious health concern worldwide due to its rising prevalence. Hypertension (HT) frequent comorbidity of T2DM, with the co-occurrence both conditions increasing risk diabetes-associated complications. Inflammation and oxidative stress (OS) have been identified as leading factors in development progression T2DM HT. However, OS inflammation processes associated these two comorbidities are not fully understood. This study aimed explore changes levels plasma urinary inflammatory biomarkers, along mitochondrial biomarkers connected dysfunction (MitD). These markers may provide more comprehensive perspective disease from no diabetes, prediabetes, coexisting HT cohort patients attending clinic Australia. Three-hundred eighty-four participants were divided into four groups according status: 210 healthy controls, 55 prediabetic patients, 32 87 (T2DM+HT). Kruskal-Wallis χ2 tests conducted between detect significant differences for numerical categorical variables, respectively. For transition prediabetes interleukin-10 (IL-10), C-reactive protein (CRP), 8-hydroxy-2'-deoxyguanosine (8-OHdG), humanin (HN), p66Shc most discriminatory generally displaying elevated addition disrupted function revealed by HN. Disease T2DM+HT indicated lower through IL-10, interleukin-6 (IL-6), interleukin-1β (IL-1β), 8-OHdG oxidized glutathione (GSSG) levels, likely antihypertensive medication use +HT patient group. The results also better this group shown higher HN which can be attributed use. monocyte chemoattractant protein-1 (MCP-1) appeared independent medication, providing an effective biomarker even presence suggest review discriminating stages or absence Our further indicate usefulness use, especially respect known involvement progression, highlighting specific during therefore allowing targeted individualized treatment plan.

Язык: Английский

Процитировано

26

Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account DOI Open Access

Roberta Vitale,

Stefania Marzocco, Ada Popolo

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7477 - 7477

Опубликована: Июль 8, 2024

Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) one most used anthracyclines in treatment many tumors, but development acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on effects long-term Doxo administration, recent data show that cardiomyocyte damage an early event induced by after a single administration can be followed progressive functional decline, leading to overt heart failure. The knowledge molecular mechanisms involved stage Doxo-induced paramount importance treating and/or preventing it. This review aims illustrate thought underlie cardiotoxicity, such as oxidative nitrosative stress, inflammation, mitochondrial dysfunction. Moreover, here we report from both vitro vivo indicating new therapeutic strategies prevent cardiotoxicity.

Язык: Английский

Процитировано

15

A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms DOI Creative Commons
András Nagy, Denise Börzsei, Alexandra Hoffmann

и другие.

Cardiovascular Drugs and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Март 16, 2024

Abstract While oncotherapy has made rapid progress in recent years, side effects of anti-cancer drugs and treatments have also come to the fore. These include cardiotoxicity, which can cause irreversible cardiac damages with long-term morbidity mortality. Despite continuous in-depth research on drugs, an improved knowledge underlying mechanisms cardiotoxicity are necessary for early detection management risk. Although most reviews focus cardiotoxic effect a specific individual chemotherapeutic agent, aim our review is provide comprehensive insight into various agents that induced their mechanisms. Characterization these underpinned by animal models clinical studies. In order gain complex mechanisms, we emphasize role inflammatory processes oxidative stress chemotherapy-induced changes. A better understanding identification interplay between chemotherapy inflammatory/oxidative hold some promise prevent or at least mitigate cardiotoxicity-associated mortality among cancer survivors.

Язык: Английский

Процитировано

12

Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin DOI
Nuri Kim,

Soonyoung Kwon,

Gayoung Kwon

и другие.

Journal of Controlled Release, Год журнала: 2024, Номер 369, С. 351 - 362

Опубликована: Апрель 3, 2024

Язык: Английский

Процитировано

11

SIRT1 signaling pathways in sarcopenia: Novel mechanisms and potential therapeutic targets DOI Open Access
Luning Yang,

Di Liu,

Shide Jiang

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 177, С. 116917 - 116917

Опубликована: Июнь 21, 2024

Sarcopenia is an aging-related skeletal disease characterized by decreased muscle mass, strength, and physical function, severely affecting the quality of life (QoL) elderly population. Sirtuin 1 (SIRT1), as a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases, has been reported to participate in various signaling pathways exert protective effect on many human diseases. SIRT1 functioned important role occurrence progression sarcopenia through regulating key related protein homeostasis, apoptosis, mitochondrial dysfunction, insulin resistance autophagy muscle, including SIRT1/Forkhead Box O (FoxO), AMP-activated kinase (AMPK)/SIRT1/nuclear factor κB (NF-κB), SIRT1/p53, AMPK/SIRT1/peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), SIRT1/live B1 (LKB1)/AMPK pathways. However, specific mechanisms these processes have not fully illuminated. Currently, several SIRT1-mediated interventions preliminarily developed, such activator polyphenolic compounds, exercising calorie restriction. In this review, we summarized predominant involved therapeutic modalities targeting for prevention prognosis sarcopenia.

Язык: Английский

Процитировано

11

Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy DOI Creative Commons

Sampat Singh Tanwar,

Sumeet Dwivedi,

Sheema Khan

и другие.

The Egyptian Heart Journal, Год журнала: 2025, Номер 77(1)

Опубликована: Март 10, 2025

Abstract Background Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities the heart muscle. It classified into primary (genetic, mixed, or acquired) secondary categories, resulting in various phenotypes including dilated, hypertrophic, restrictive patterns. Hypertrophic cardiomyopathy, most common form, can cause exertional dyspnea, presyncope, sudden cardiac death. Dilated cardiomyopathy typically presents with failure symptoms, while rarer often associated systemic diseases. Diagnosis involves comprehensive evaluation history, physical examination, electrocardiography, echocardiography. Treatment options range from pharmacotherapy lifestyle modifications to implantable cardioverter-defibrillators transplantation refractory cases. Main body Anthracyclines, particularly doxorubicin, have emerged as crucial components cancer treatment, demonstrating significant antitumor activity across malignancies. These drugs become standard numerous chemotherapy regimens, improving patient outcomes. However, their use severe cardiotoxicity, failure. The mechanisms anthracycline action toxicity are complex, involving DNA damage, iron-mediated free radical production, disruption cardiovascular homeostasis. Doxorubicin-induced (DIC) complication treatment poor prognosis limited effective treatments. pathophysiology DIC multiple mechanisms, oxidative stress, inflammation, mitochondrial calcium homeostasis disorder. Despite extensive research, no for established currently available. Dexrazoxane only FDA-approved protective agent, but it has limitations. Recent studies explored potential therapeutic approaches, natural drugs, endogenous substances, new dosage forms, herbal medicines. lack experimental models incorporating pre-existing limits understanding efficacy. Conclusion Cardiomyopathy, whether secondary, poses clinical challenge due its varying etiologies advanced stages. Anthracycline-induced chemotherapy, doxorubicin being notable contributor. advancements therapies, cardiotoxic effects anthracyclines necessitate further investigation preventive strategies interventions improve

Язык: Английский

Процитировано

2